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Originality-Significance Statement 29 
Irritable bowel syndrome (IBS) is a common, long-term condition that affects the large intestine and 30 
can occur with dramatically different symptoms from one person to another, especially in terms of 31 
their bowel habits. This study suggests, for the first time, that a network of correlations among (i) 32 
fecal Clostridiales bacteria, (ii) short-chain fatty acids, (iii) immunological factors, and (iv) clinical 33 
data may differentiate IBS subtypes. In this study, we propose that the bacterial taxa and SCFAs 34 
that distinguish the IBS categories may also serve as potential subtype-specific therapeutic targets 35 
for the management of IBS, which is the most prevalent functional gastrointestinal disorder in the 36 
Western world.  37 
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Summary 38 
Irritable bowel syndrome (IBS), a common functional gastrointestinal disorder, is classified 39 
according to bowel habits as IBS with constipation (IBS-C), with diarrhea (IBS-D), with alternating 40 
constipation and diarrhea (IBS-M), and unsubtyped (IBS-U). The mechanisms leading to the 41 
different IBS forms are mostly unknown. This study aims to evaluate whether specific fecal 42 
bacterial taxa and/or short-chain fatty acids (SCFAs) can be used to distinguish IBS subtypes and 43 
are relevant for explaining the clinical differences between IBS sub-categories. We characterized 44 
five fecal samples collected at 4-weeks intervals from 40 IBS patients by 16S rRNA gene profiling 45 
and SCFA quantification. Finally, we investigated the potential correlations in IBS subtypes 46 
between the fecal microbial signatures and host physiological and clinical parameters. We found 47 
significant differences in the distribution of Clostridiales OTUs among IBS subtypes and reduced 48 
levels of SCFAs in IBS-C compared to IBS-U and  IBS-D patients. Correlation analyses showed 49 
that the diverse representation of Clostridiales OTUs between IBS subtypes was associated with 50 
altered levels of SCFAs; furthermore, the same OTUs and SCFAs were associated with the fecal 51 
cytokine levels and stool consistency. Our results suggest that intestinal Clostridiales and SCFAs 52 
might serve as potential mechanistic biomarkers of IBS subtypes and represent therapeutic targets. 53 
 54 
Key words: fecal microbiota, IBS, short-chain fatty acids, Clostridiales, 16S rRNA gene profiling. 55 
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Introduction 56 
Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal disorder in the 57 
Western world. Although it does not have a lethal prognosis, IBS may significantly decrease the 58 
quality of life of patients depending on the severity of symptoms, which characteristically include 59 
abdominal pain, bloating, distension and altered bowel habits (Mearin et al., 2016). 60 
IBS is a widely heterogeneous condition in terms of etiology, pathogenesis and clinical 61 
presentation. In a recent paper, Collins S. M. proposed to explain the intestinal dysfunctions 62 
associated with IBS through a gut-microbiota-centered model (Collins, 2014). According to this 63 
model, triggers such as extensive antibiotic use, infections and/or stress affect host functions, 64 
including mucin production, gut motility and hormone secretion, lead to dysbiosis (i.e., structural 65 
and functional alterations of the intestinal microbial ecosystem; IME), which in turn, promotes 66 
chronic gut dysfunction. Hence, Collins’ model highlights the central role of the intestinal 67 
microbiota in IBS, in agreement with clinical evidence of the benefits generated by gut microbiota-68 
targeting strategies, such as the use of the poorly absorbed antibiotic rifaximin (Li et al., 2016) and 69 
probiotics (O'Mahony et al., 2005; Guglielmetti et al., 2011). Accordingly, gut dysbiosis was often 70 
observed to be a common alteration associated with IBS (Taverniti and Guglielmetti, 2014; Zhuang 71 
et al., 2017). Contextually, several possible bacterial signatures have been proposed to distinguish 72 
IBS patients from healthy controls, such as increases in certain Ruminococcus phylotypes, reduction 73 
of bifidobacteria, or expansion of Proteobacteria and Veillonella spp. (Taverniti and Guglielmetti, 74 
2014; Rajilic-Stojanovic et al., 2015). In addition, the available scientific literature also describes 75 
the significant role played by altered levels of short-chain fatty acids (SCFAs) in IBS (Ringel-Kulka 76 
et al., 2015; Camilleri et al., 2016; Farup et al., 2016). For instance, Farup and colleagues proposed 77 
that propionate and butyrate may act as discriminatory factors to differentiate healthy subjects from 78 
subjects with IBS (Ringel-Kulka et al., 2015). By contrast, in the study of Ringel-Kulka et al., 79 
SCFAs were found to discriminate IBS from healthy controls only when based on the subtype 80 
Page 4 of 31
Wiley-Blackwell and Society for Applied Microbiology
For Peer Review Only
5 
 
(Ringel-Kulka et al., 2015). Therefore, although they are recognized as biomarkers for IBS (Kim et 81 
al., 2017), SCFAs require further study to elucidate their actual role in IBS. 82 
IBS is conventionally classified into four subtypes according to bowel habits: IBS with 83 
constipation (IBS-C), IBS with diarrhea (IBS-D), and IBS with alternating constipation and diarrhea 84 
(mixed IBS, IBS-M) as well as unsubtyped IBS (IBS-U) (Mearin et al., 2016). The diverse 85 
mechanisms underlying the pathophysiology of IBS subtypes remain unknown, and validated 86 
mechanistic biomarkers for the IBS subtypes are not available (Kim et al., 2017). IBS-subtype 87 
specific alterations of the intestinal microbiota have been reported (Malinen et al., 2005; Kassinen 88 
et al., 2007; Lyra et al., 2009; Carroll et al., 2010; Pozuelo et al., 2015; Tap et al., 2017). For 89 
instance, Tap et al. reported that IBS-D patients had more Methanobacteriales than patients with 90 
other IBS subtypes (Tap et al., 2017), whereas Pozuelo et al. reported evidence for an association 91 
between lower microbial diversity and a decreased abundance of butyrate-producing bacteria in 92 
patients with IBS-D and IBS-M (Pozuelo et al., 2015). However, data concerning the differences in 93 
the gut microbiota composition of the IBS subtypes are contradictory and are often based on 94 
methods that have low discriminatory power (Taverniti and Guglielmetti, 2014). 95 
Inspired by the above considerations, this study was conducted to evaluate whether specific fecal 96 
bacterial taxa and/or colonic SCFAs can be used to distinguish IBS subtypes and are relevant for 97 
defining the mechanisms that lead to the clinical differences between IBS sub-categories. To fulfil 98 
this aim, we characterized the IME in IBS subtypes by means of 16S ribosomal RNA (rRNA) gene 99 
profiling and SCFA quantification of fecal samples derived from a multicenter intervention trial that 100 
we recently performed to assess the effect of a probiotic preparation (L. casei DG
®
; Lactobacillus 101 
paracasei CNCM I-1572) on the IBS symptoms of 40 patients (Cremon et al., 2017). In addition, 102 
the clinical and immunological data collected during the trial were used to investigate potential 103 
correlations in IBS subtypes between the IME and host physiological and clinical parameters, 104 
including bowel habits, depression/anxiety scores, and fecal levels of IgA and cytokines. We 105 
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propose that the bacterial taxa and SCFAs that were identified can be used as to distinguish IBS 106 
subtypes and can also serve as potential therapeutic targets. 107 
 108 
Results 109 
The overall bacterial diversity of the fecal microbiota does not discriminate among IBS subtypes 110 
16S rRNA gene profiling was performed on 198 fecal samples (5 fecal samples collected from 39 111 
subjects and 3 fecal samples from a subject who dropped out after visit V3), generating a total of 112 
16,963,222 filtered high-quality sequence reads (a mean of 138,413 reads per sample). Rarefaction 113 
curves demonstrated that most fecal microbiota diversity had been covered (not shown). The 114 
Unifrac algorithm was used to investigate inter-sample β-diversity. The intra-patient variability 115 
observed among the five samples analyzed is shown in Supplementary figure S1 according to the 116 
two main components extracted. 117 
In the subsequent analyses, besides considering the data of a single 16S rRNA gene profiling 118 
determination per subject at baseline (single profiling data, corresponding to the data obtained from 119 
the analysis of the first fecal sample per subject, collected at visit V1; n=40), we also performed the 120 
analyses with data corresponding to the medians of five 16S rRNA gene profiling determinations 121 
per patient (median profiling data, corresponding to the median value of data obtained from the 122 
analysis of all fecal samples per subject, which were collected at visits from V1 to V5; n=39). 123 
Afterwards, we investigated the β-diversity of the different types of IBS. This analysis revealed 124 
that both weighted and unweighted Unifrac cannot distinguish fecal samples on the basis of IBS 125 
subtypes either with individual (Supplementary Figures S2) or median (Supplementary Figures S1 126 
and Fig. 1) profiling data. 127 
Next, intra-subject taxonomic richness and evenness (α-diversity) were analyzed using five 128 
algorithms; namely, observed OTUs, Chao1, Faith's Phylogenetic Diversity, and Shannon and 129 
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Simpson indexes. The α-diversity indexes of the IBS subtypes did not significantly differ with 130 
either individual or median profiling data (Supplementary Figure S3). 131 
The microbiota profiling data were then stratified by enterotyping based on the relative 132 
abundances of the bacterial genera (Gargari et al., 2016). An optimal number of three groups of 133 
samples was generated; nonetheless the Silhouette coefficient, which validates the consistency 134 
within groups of data, was too low to consider the clustering reliable (Supplementary Figure S4). 135 
Notably, the taxonomic overview of all 198 IBS fecal samples analyzed revealed that the first seven 136 
most abundant genera belonged to the Firmicutes Gram-positive order Clostridiales (Supplementary 137 
Figure S5A); in particular, Clostridiales accounted for approximately 75 % of the detected bacteria; 138 
in contrast, the relative abundance of members of the order Bacteroidales was lower than 10 % 139 
(Supplementary Figure S5A). On the contrary, in our previous studies, we found that Bacteroidales 140 
(particularly the genera Bacteroides and Prevotella) were the dominant genera of the fecal 141 
microbiota in healthy volunteers (Ferrario et al., 2014; Gargari et al., 2016). Therefore, at the end of 142 
the IBS trial, we analyzed additional fecal samples collected from 16 healthy adults through 16S 143 
rRNA gene profiling and adopting the same protocol used for the IBS samples with the sole aim of 144 
assessing whether the observed expansion of Clostridiales compared to Bacteroidales is a bona fide 145 
microbiological feature of the investigated IBS patients. The results showed that Clostridiales are 146 
largely dominant also in the feces of control subjects (Fig. S5B), demonstrating that the alteration of 147 
the Clostridiales/Bacteroidales ratio observed in IBS samples depended on technical issues, most 148 
likely the protocol used for the extraction of metagenomic DNA from the feces. Indeed, differently 149 
from the present study, in our previous works, we extracted fecal metagenomic DNA using a 150 
commercial kit that did not include a cell-breaking step using bead beater, plausibly resulting in the 151 
underestimation of the Gram-positive bacteria (e.g., Clostridiales), which have a stronger cell walls 152 
than Gram-negative cells (e.g., Bacteroidales). 153 
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Overall, these data indicate that the bacterial ecological diversity indexes of the fecal microbiota 154 
do not vary significantly among IBS subtypes. The results of this study showed a general 155 
dominance of Clostridiales in the fecal samples collected from both IBS and control subjects. 156 
 157 
IBS-C and IBS-D fecal samples are differently enriched in OTUs ascribed to Clostridiales 158 
Subsequently, microbiomic data were examined with the DESeq2 negative binomial distribution 159 
method to infer differential relative abundances at the OTU level between IBS subtypes (IBS-C, 160 
n=12; IBS-D, n=11; IBS-M, n=3; IBS-U, n=11). The analysis was performed both on V1 and V1-5 161 
profiling data; the IBS-M subtype was excluded because too few patients (n=3) had this subtype to 162 
allow the identification of significant differences. We found that several OTUs discriminated 163 
among the three IBS subtypes considered (Fig. 2 and Supplementary Figure 6). A summary of the 164 
number of significantly different OTUs was plotted as a Venn diagram (Fig. 2A). Specifically, the 165 
analysis of median profiling data revealed 26 significantly different OTUs between IBS-U and IBS-166 
C, 11 of which were also found while analyzing individual profiling data (Fig. 2B and 167 
Supplementary Figure 6); 19 OTUs distinguished IBS-U from IBS-D, 6 of which were also found 168 
while analyzing individual profiling data (Fig. 2B and Supplementary Figure 6). The greatest 169 
number of dissimilarities was found between IBS-C and IBS-D: 85 OTUs had significantly 170 
different relative abundances, 39 of which were also found while analyzing individual profiling data 171 
(Fig. 2B and Supplementary Figure 6). Most of the discriminating OTUs were taxonomically 172 
ascribed to the order Clostridiales (Fig. 2B and Supplementary Figure 6); in particular, IBS-C was 173 
distinguished from IBS-D by numerous OTUs associated with Clostridiales belonging to the 174 
families Ruminococcaceae (in particular, the genus Ruminococcus) and Lachnospiraceae. In 175 
addition, two OTUs ascribed to Bifidobacterium adolescentis were increased in IBS-C, whereas 176 
OTUs associated with the order Bacteroidales (i.e., Bacteroides caccae, Parabacteroides distasonis 177 
and Prevotella copri) and to the Firmicutes species Eubacterium biforme were enriched in the IBS-178 
D samples (Fig. 2B and Supplementary Figure 6). 179 
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Overall, these results indicate that the fecal microbiota of IBS-C and IBS-D are characterized by 180 
a different distribution of Clostridiales taxonomic units, whereas the fecal microbiota of the IBS-U 181 
samples possessed compositional features that were intermediate between those of the IBS-C and 182 
IBS-D samples. 183 
 184 
IBS subtypes are characterized by altered fecal levels of short-chain fatty acids 185 
The intestinal levels of the short-chain fatty acids (SCFAs) acetate, butyrate, isobutyrate, valerate, 186 
isovalerate and propionate were quantified in the IBS fecal samples and used to characterize the 187 
IBS subtypes. To determine the fecal microbiota composition, the  SCFAs were analyzed 188 
considering the levels determined in a single fecal sample per patient (single analysis SCFA levels, 189 
n=37; Supplementary Figure 7) and the median values of five measurements per patient (median 190 
SCFA levels, n=37; Fig. 3A). SCFAs were also quantified in the IBS-M fecal samples, but this 191 
subgroup was excluded from the statistical analyses due to the limited number of patients (n=3). In 192 
addition, the SCFA levels in the IBS samples were compared with those of healthy subjects (n=25), 193 
which were determined in a previous study (Gargari et al., 2016). 194 
We found that the fecal levels of SCFAs clearly distinguished the IBS-C samples from the IBS-195 
D and IBS-U samples. In detail, the levels of acetate, butyrate, propionate and valerate were 196 
significantly higher in IBS-D than in IBS-C. In addition, fecal concentrations of acetate, butyrate 197 
and propionate were higher in IBS-U than in IBS-C. Compared to all IBS samples considered 198 
together, the fecal level of acetate was significantly lower in IBS-C, whereas the fecal level of 199 
valerate was significantly higher in IBS-D (Fig. 3A). No significant differences among the IBS 200 
subgroups were observed for isobutyrate and isovalerate (Fig. 3A). 201 
We did not find significant differences between the IBS samples and healthy controls with the 202 
sole exception of isovalerate, which was lower in IBS. Nonetheless, notably, numerous significant 203 
differences emerged when the IBS subtypes were considered separately. We found that acetate and 204 
propionate where significantly higher in IBS-D compared to healthy controls, whereas acetate and 205 
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valerate were significantly lower in IBS-C than controls; globally, the total concentration of SCFAs 206 
was significantly higher in IBS-D and lower in IBS-C compared to healthy controls, whereas IBS-U 207 
levels were not dissimilar from the controls (Fig. 3A and Supplementary Figure 7). 208 
Subsequently, a principal component analysis (PCA) was performed to discriminate samples 209 
based on fecal SCFA levels. As evidenced by the PCA bi-plot depicted in Fig. 3B, increased levels 210 
of acetate, butyrate and propionate characterized the IBS-D samples and distinguished them from 211 
the IBS-C samples (R=0.133; P = 0.011 according to ANOSIM test); on the other hand, IBS-U and 212 
the healthy controls are located in an intermediate area of the plot. 213 
Overall, these data indicate that significant differences in the fecal levels of SCFAs can be found 214 
between healthy adults and IBS patients only if IBS subtypes are considered; specifically, IBS-D 215 
samples are characterized by the increase of and IBS-C samples are characterized by the decrease of 216 
the fecal levels of SCFAs. Contrarily, fecal SCFAs were not dissimilar between the IBS-U and 217 
control samples. 218 
 219 
The intestinal microbial ecosystem reflects clinical features of IBS subtypes 220 
Finally, we performed correlation analyses between the fecal microbial ecology data and clinical 221 
parameters of the IBS patients to find relationships between IME and the clinical parameters. The 222 
correlation analysis was performed as described in the materials and methods section using a non-223 
parametric correlation test (Spearman and Kendall). To this end, we used as predictors the fecal 224 
levels of SCFAs or the relative abundances of the OTUs that we found to be significantly different 225 
between IBS subtypes; the dependent variables considered were SCFAs, Bristol stool scale data (to 226 
assess bowel habits), abdominal pain/discomfort score, fecal levels of IgA and cytokines (TGFβ, 227 
IL6, IL8, IL10, IL12, IFNγ, and TNFα), and HADS and SF-12 questionnaire data (to evaluate 228 
anxiety and depression, and quality of life, respectively) (Cremon et al., 2017). As with the previous 229 
analyses, correlations were estimated based on data collected at a single time point (V1) and on 230 
median data for multiple time points (V1-V5). 231 
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We found that host parameters were significantly correlated with numerous OTUs (Fig. 2B). 232 
Notably, we found that most Clostridiales OTUs that were enriched in IBS-C samples were 233 
negatively correlated with the fecal SCFAs propionate and butyrate, whereas several Clostridiales 234 
OTUs that were overrepresented in IBS-D were positively correlated with acetate and valerate (Fig. 235 
2B). Moreover, most IBS-C-enriched OTUs that were inversely linked to SCFAs were positively 236 
correlated with several cytokines (particularly IL10) and were negatively correlated with IgA. 237 
Conversely, several IBS-D-enriched OTUs that were positively associated with SCFAs were also 238 
positively correlated with the fecal type as determined using the Bristol stool scale (Fig. 2B). 239 
Accordingly, we found a positive correlation between the fecal type and acetate, butyrate and 240 
valerate (Fig. 4). In addition, notably, IgA resulted positively correlated with evacuation frequency 241 
and negatively correlated with IL10 and TNFα (Fig. 4). 242 
Overall, these results indicate that the differential representation of Clostridiales OTUs between 243 
IBS subtypes is associated with altered levels of intestinal SCFAs; then, in turn, both OTUs and 244 
SCFAs are associated with stool consistency. 245 
 246 
Discussion 247 
The primary aim of the present study was to characterize the gut microbiota in IBS subtypes. To 248 
achieve this, we carried out 16S rRNA gene profiling and SCFAs quantification in 198 fecal 249 
samples obtained from 40 IBS patients enrolled in 5 Italian hospitals (Cremon et al., 2017). 250 
Temporal instability is a distinguishing feature of the intestinal microbiota associated with IBS 251 
(Matto et al., 2005; Maukonen et al., 2006; Durban et al., 2013); for this reason, it was suggested 252 
that studies aimed at characterizing the gut microbiota in IBS should include multiple time points 253 
(Collins, 2014). Accordingly, in this study, we based microbiota analyses on data obtained from 254 
five fecal samples collected at 4-week intervals from each patient. These samples derived from a 255 
randomized cross-over intervention trial that assessed the clinical efficacy of a probiotic product. 256 
Although we are aware that the treatment may have affected the intestinal microbiota of IBS 257 
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patients, we believe that the benefits of using five different fecal samples per subject are greater 258 
than the possible bias incurred and may permit a more reliable identification of gut microbiota 259 
biomarkers for IBS subtypes, for the following reason: All the analyses were carried out 260 
considering only data at baseline (i.e., originating from the analysis of the fecal samples collected at 261 
visit V1, when no product or placebo had yet been administered to the patients; single sample data 262 
analysis); single sample data analysis implies a mistake due to the great variability of the gut 263 
microbiota in IBS subjects, whereas the analysis with the median data of five samples per subject 264 
may determine an error due to the subject-dependent response to the probiotic treatment. The two 265 
potential errors are compensated by the combined use of the results derived from the analyses of 266 
single and median data. We believe, therefore, that those OTUs and SCFAs that yielded 267 
significantly different results between IBS subtypes based on the analysis of both data populations 268 
can be very plausibly considered valid microbial signatures. 269 
Several studies focused on the characterization of the microbiota in IBS, with particular attention 270 
being paid to the identification of microbial markers distinguishing this dysfunction from the 271 
healthy condition (Zhuang et al., 2017); however, much less attention has been spent to compare the 272 
IMEs of IBS subtypes. In this context, Tap and collaborators recently reported that neither the 273 
richness nor the variability of the intestinal microbiota differed among IBS groups (Tap et al., 274 
2017). Accordingly, we did not find significant differences in either α- or β-diversity among the 275 
IBS subtypes. In a previous study, Jeffery et al. (Jeffery et al., 2012) used pyrosequencing of the 276 
16S rRNA gene to determine the microbiota composition in fecal specimens from 37 IBS patients. 277 
Notably, they identified distinct IBS patient subsets; however, these did not correspond to the 278 
traditional IBS subtypes (Jeffery et al., 2012). On the contrary, in the present study, we found that 279 
the relative abundance of numerous OTUs were significantly different among the IBS subtypes. In 280 
particular, we report here that major differences exist in Clostridiales OTUs between IBS-C and 281 
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IBS-D feces; conversely, IBS-U fecal samples differed much less from IBS-C and IBS-D in terms 282 
of OTUs. 283 
A rapidly expanding body of literature is demonstrating the clinical efficacy of dietary patterns 284 
based on drastically reducing fermentable oligo-, di-, mono-saccharides and polyols (the low-285 
FODMAP diet) (Eswaran et al., 2016). Reportedly, FODMAPs are preferential fermentation 286 
substrates for the intestinal Clostridiales bacteria (Flint et al., 2012); accordingly, several trials have 287 
demonstrated that these bacteria may be affected by reduced FODMAP intake (Chumpitazi et al., 288 
2014; Halmos et al., 2015; McIntosh et al., 2016). Therefore, we speculate that Clostridiales 289 
bacteria in the gut of IBS patients may represent a therapeutic target modulated by the low-290 
FODMAP diet. 291 
Many OTUs that distinguished IBS-C from IBS-D samples belonged to the Clostridiales families 292 
Ruminococcaceae and Lachnospiraceae. The importance of these gut bacteria in IBS was also 293 
evidenced by the study of Tap et al., who defined a composite gut microbial signature for IBS 294 
severity constituted by 90 OTUs; at the family level, these principally included OTUs within 295 
Lachnospiraceae and Ruminococcaceae (Tap et al., 2017). Lachnospiraceae and Ruminococcaceae, 296 
which are the most commonly retrieved families in the active intestinal microbiota (Peris-Bondia et 297 
al., 2011), are considered the principal intestinal microorganisms that degrade plant carbohydrates 298 
(Wolin et al., 2003; Chassard et al., 2007; Flint et al., 2012), producing SCFAs as their main 299 
catabolites (Flint et al., 2012). These bacterial families include the most important butyrate-300 
producing microorganisms in the human gut such as the genera Faecalibacterium and Roseburia 301 
(Barcenilla et al., 2000; Louis et al., 2010) as well as bacteria that can produce acetate from 302 
reductive acetogenesis (Bernalier et al., 1996; Rey et al., 2010) and butyrate or propionate from 303 
lactate utilization (Duncan et al., 2004; Rios-Covian et al., 2016). 304 
Considering the above-mentioned literature, the observed differential OTU distribution between 305 
IBS-C and IBS-D samples suggest that the IBS subtypes have dissimilar fecal levels of SCFAs. 306 
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Accordingly, we found significantly lower levels of acetate, butyrate, propionate and valerate in 307 
IBS-C samples. Notably, these results were also confirmed when considering the data calculated as 308 
the medians of five determinations per subject over approximately 4 months, confirming the 309 
observed differences in SCFAs between IBS sub-categories. 310 
The scientific literature on intestinal SCFAs in IBS is quite limited and contradictory, showing 311 
no altered, augmented, or decreased levels compared to healthy controls (Mortensen et al., 1987; 312 
Treem et al., 1996; Tana et al., 2010; Halmos et al., 2014; Rajilic-Stojanovic et al., 2015). In our 313 
study, we did not find significant differences in the fecal levels of the main SCFAs when the data 314 
from all IBS samples were compared with the fecal SCFA concentrations found in healthy adults as 315 
determined using the same protocol in a recent study (Gargari et al., 2016). Nonetheless, substantial 316 
differences emerged when the IBS subtypes were considered independently. Our data are in accordance 317 
with the study of Ringel-Kulka et al. (Ringel-Kulka et al., 2015), in which IBS-D patients (n=42) 318 
were shown to have significantly higher fecal levels of acetate, propionate and butyrate than IBS-C 319 
patients (n=26). Interestingly, in this study, the authors also found that fecal SCFA concentrations 320 
were negatively correlated with colon transit time. This result is potentially in agreement with the 321 
positive correlation we found between fecal type (determined using the Bristol stool scale) and 322 
acetate, butyrate and valerate levels.  323 
The link between colon transit time and intestinal SCFAs in IBS subtypes can be explained by 324 
two possible opposite mechanisms (Ringel-Kulka et al., 2015): (1) compared to IBS-C, IBS-D 325 
patients are characterized by increased colonic fermentation, which leads to higher fecal levels of 326 
SCFAs, thereby stimulating intestinal motility (Fukumoto et al., 2003) and reducing transit time; or 327 
(2) decreased transit time in IBS-D patients slows down SCFA absorption, leading to higher SCFA 328 
concentrations in the feces compared to those in IBS-C patients. Here, we showed that several 329 
OTUs were significantly enhanced in IBS-D compared to IBS-C, and this was correlated positively 330 
with fecal levels of SCFAs (especially acetate) and fecal type; at the same time, a number of OTUs 331 
that were expanded in IBS-C were inversely correlated with SCFAs. Nevertheless, both explanatory 332 
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scenarios are still valid. On one hand, it is possible that the different distribution of intestinal 333 
bacteria is responsible for the dissimilar concentration of SCFAs in IBS subtypes. On the other 334 
hand, it can be speculated that bacteria in the colon may be differently affected by modified 335 
intestinal transit (for instance, due to variable adhesion abilities and/or cell reproduction rates 336 
among the diverse bacteria) with a consequent modification of the relative distribution of bacterial 337 
taxa in feces. However, two facts might support the first scenario: (i) most of the fecal bacteria that 338 
distinguish IBS-C from IBS-D are members of taxa known to be SCFA producers and (ii) it is 339 
known that SCFAs stimulate colonic motility and may increase the osmotic load leading to diarrhea 340 
(Fritz et al., 2005). In summary, we think it is reasonable to hypothesize a self-perpetuating 341 
mechanism in which an initial modified colon transit time (determined by any possible trigger, such 342 
as gut infections or intensive antibiotic use) gives rise to intestinal dysbiosis, which, in turn, leads to 343 
altered intestinal levels of SCFAs that may exacerbate or maintain the altered intestinal motility. 344 
Reportedly, immune system activation is involved in the pathophysiology of IBS (Barbara et al., 345 
2011). In particular, cytokines are mediators of immune responses that can be involved in motor 346 
dysfunctions and visceral pain (Dinan et al., 2006). In this study, correlation analyses revealed 347 
significant positive associations of IgA and IFNγ with evacuation frequency. Little information is 348 
available in the scientific literature concerning intestinal IgA in IBS; nonetheless, our results are 349 
consistent with those of Wahnschaffe et al., who reported a significant decrease in stool frequency 350 
and intestinal IgA levels under a gluten-free diet in a subgroup of celiac IBS patients (Wahnschaffe 351 
et al., 2001). In addition, IFNγ was shown to be increased in the gut of IBS patients and to reduce 352 
the expression of the serotonin transporter (SERT), thereby resulting in increased serotonin levels 353 
and motility (Barbaro et al., 2016). 354 
 355 
Conclusions 356 
This study suggests that the altered distribution of bacteria inside the Gram-positive order 357 
Clostridiales can be used to distinguish the intestinal microbial ecosystem of IBS subtypes and 358 
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plausibly contributes to the observed altered fecal levels of SCFAs. The main limitation of this 359 
study is the limited sample size. Nonetheless, we believe that the repeated measures per patient 360 
combined with the bioinformatics analysis that we used was suitable to identify key microbial 361 
signatures that can define the IBS types. Although we are aware that the results presented here are 362 
not proof of a cause-effect relationship between IME and clinical outputs in IBS, we hypothesize 363 
that intestinal Clostridiales and colonic SCFAs can be used as mechanistic biomarkers of IBS 364 
subtypes and also potentially represent therapeutic targets. In addition, this study supports the 365 
notion that distinct therapeutic approaches should be developed for the different IBS subtypes. 366 
 367 
Experimental procedures 368 
Patients and study protocol 369 
Eligible patients with symptoms meeting the Rome III criteria for IBS diagnosis were recruited in 370 
five Italian hospitals as previously described (Cremon et al., 2017). In brief, the inclusion criteria 371 
comprised a positive diagnosis of IBS (of any subtype), age between 18 and 65 years, negative 372 
colonoscopy or barium enema examination within the previous 2 years, and negative relevant 373 
additional screening or consultation whenever appropriate. Patients were excluded if they were 374 
pregnant, breast-feeding, or not using reliable methods of contraception. The exclusion criteria also 375 
included the presence of intestinal organic diseases, such as celiac disease, as ascertained by the 376 
detection of anti-transglutaminase antibodies; diverticular disease; or inflammatory bowel diseases 377 
(IBDs; e.g., Crohn's disease, ulcerative colitis, infectious colitis, ischemic colitis, or microscopic 378 
colitis); previous major abdominal surgery; untreated food intolerance, such as ascertained or 379 
suspected lactose intolerance as defined by an anamnestic evaluation or, if appropriate, a lactose 380 
breath test; consumption of probiotics or topical and/or systemic antibiotic therapy during the 381 
month before study enrolment; systematic/frequent consumption (i.e., once weekly or more 382 
frequent) of contact laxatives; presence of any relevant organic, systemic, or metabolic disease as 383 
assessed by the medical history, appropriate consultations, and laboratory tests; or abnormal 384 
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laboratory values deemed to be clinically significant on the basis of predefined values. Upon 385 
enrollment, all patients were asked to maintain their habitual diet. The gender, age and subtypes of 386 
the enrolled population are reported in Supplementary Table 1. The enrolled patients were included 387 
in a multicenter, randomized, double-blind, cross-over, placebo-controlled, pilot trial (PROBE-IBS 388 
trial, registered under the ClinicalTrial.gov No. NCT02371499), whose primary endpoint was the 389 
assessment of the effect of Lactobacillus paracasei CNCM I-1572 (LCDG) on the IBS clinical 390 
symptoms. The design and results of the PROBE-IBS trial are described in (Cremon et al., 2017). In 391 
brief, PROBE-IBS consisted of a two-week run-in phase, after which the volunteers were randomly 392 
assigned to take either LCDG twice daily for four weeks or a placebo (treatment A). At the end of 393 
this phase, the patients entered a four-week washout period before crossing over to the alternate 394 
treatment (twice daily for four weeks: treatment B), followed by a four-week follow-up period. The 395 
patients collected and delivered a fecal sample before and after treatment A (at visits V1 and V2, 396 
respectively), before and after treatment B (at visits V3 and V4, respectively), and after the follow-397 
up period (visit V5). The number of patients was calculated before the recruitment started. 398 
Collected data and missing samples 399 
A total of 40 IBS patients (IBS-C, n=12; IBS-D, n=14; IBS-M, n=3; IBS-U, n=11) were included 400 
in the study. IBS subtypes were classified according to the Rome III criteria and based on Bristol 401 
Stool Form scale characteristics (Longstreth et al., 2006). Information and biological specimens 402 
were collected every four weeks at five consecutive time points (visits V1-V5) according to the trial 403 
design described by Cremon et al. (Cremon et al., 2017). One participant (belonging to the IBS-D 404 
subgroup) dropped out after visit V3 and, consequently, 198 fecal samples were collected. 16S 405 
rRNA gene profiling analyses were performed on all samples, whereas SCFAs were quantified in 406 
the 5 fecal samples of 37 patients (i.e., a total of 185 samples; IBS-C, n=12; IBS-D, n=11; IBS-M, 407 
n=3; IBS-U, n=11) due to insufficient specimens. Data from Bristol stool scale, anxiety/depression 408 
scales, and IgA and cytokine data were available as described in (Cremon et al., 2017). Correlation 409 
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analyses were performed using data from a subgroup of 150 samples (30 patients) instead of 200 410 
(40 patients) because we removed samples with immunological data below the detection limit. 411 
After the end of the study, we also included 16 control subjects (i.e., non-diseased adults without 412 
IBS). Controls were recruited to match the parameters of age and sex of the IBS patients 413 
(Supplementary Table 1). 414 
Profiling of the fecal microbiota composition 415 
Fecal samples were collected by patients and kept in refrigerator until delivery to the laboratory. 416 
Once delivered, stools were stored at -80° C until the beginning of the analysis. Metagenomic DNA 417 
was extracted from about 200 mg of feces using the PowerSoil
®
 DNA Isolation Kit (MO BIO 418 
Laboratories) according to the manufacturer’s instructions. Subsequently, the bacterial community 419 
structure was profiled by 16S rRNA gene profiling. In brief, Probio_Uni and Probio_Rev primers 420 
were used to amplify a partial region of the 16S rRNA encompassing the V3 variable region 421 
(Gargari et al., 2016). Next, amplicons wer  sequenced using Illumina MiSeq System and the 422 
resulting sequence reads were managed by means of the bioinformatic pipeline Quantitative 423 
Insights Into Microbial Ecology (QIIME) version 1.7.0 (Caporaso et al., 2010) with the GreenGenes 424 
database (version 13.5), which allowed clustering of sequences into operational taxonomic units 425 
(OTUs). Metadata have been deposited in the European Nucleotide Archive (ENA) of the European 426 
Bioinformatics Institute under accession code PRJEB18753. 427 
Quantification of fecal short-chain fatty acids (SCFAs) 428 
SCFAs were quantified in the fecal samples as previously described (Gargari et al., 2016). In brief, 429 
100 mg of stools were suspended in 2 ml of 0.001% formic acid, vortexed for 1 min, and 430 
centrifuged at 1000 x g for 2 min at 4 °C. Supernatant was recovered and pellet was extracted again 431 
as described above. Then, the two supernatants were combined and the volume adjusted to 5 ml 432 
with 0.001% formic acid solution. All extracts were stored at -20 °C until analysis, which was 433 
performed by UPLC-HR-MS on Acquity UPLC separation module (Waters, Milford, MA, USA) 434 
coupled with an Exactive Orbitrap MS through an HESI-II probe for electrospray ionization 435 
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(Thermo Scientific, San Jose, CA, USA). Column, ion source and interface conditions were 436 
reported in (Gargari et al., 2016). Elution was carried out at a flow-rate of 0.2 ml/min with solvents 437 
0.001% HCOOH in MilliQ-treated water (solvent A) and CH3OH:CH3CN (1:1 v/v, solvent B), 438 
using the following elution gradient: 0% B for 4 min, 0-15% B in 6 min, 15-20% B in 5 min, 20% 439 
for 13 min, and then return to initial conditions in 1 min. Subsequently, the UPLC eluate was 440 
analyzed in full scan MS in the range 50-130 m/z as described elsewhere (Gargari et al., 2016). 441 
External calibration curves were prepared with reagents from Sigma-Aldrich (Milan, Italy) to 442 
quantify acetic, butyric, isobutyric, isovaleric, propionic, and valeric acids in fecal samples. SCFA 443 
concentrations were expressed in mmol per kilogram of wet feces. 444 
Statistical analysis 445 
Data concerning the intestinal microbial ecosystem (16S rRNA gene profiles and SCFA 446 
quantifications) were analyzed using R statistics software (version 3.1.2) and QIIME. Significant 447 
differences were determined using the Wilcoxon-Mann-Whitney test for unpaired data. Significant 448 
differences at the OTU level between IBS subtypes were determined using differential gene 449 
expression analysis based on the negative binomial distribution method (R/Bioconductor DESeq2 450 
package); an FDR-adjusted p-value (q-value) with a cut off value of 0.1 was used for the threshold   451 
(Love et al., 2014). DESeq2 analysis was performed on both single (V1) and median (V1-5) 452 
microbiomic data. For the analysis of the median profiling data, the DESq2 model was applied to 453 
the medians of the reads counts at five time points per subject. Correlation analyses were performed 454 
using the Kendall and Spearman formulas with the items specified in the text as predictors and 455 
dependent variables. Significance was set at P≤0.05; significance in the range 0.05<P<0.10 was 456 
accepted as a trend. UNIFRAC algorithms were used to study the inter-sample diversity of the fecal 457 
microbiota composition. To define enterotypes, microbiota profiling data were analyzed based on 458 
genus relative abundance using the JSD distance and the Partitioning Around Medoids (PAM) 459 
algorithm (Gargari et al., 2016). Significant differences between groups of samples in principal 460 
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component analyses were assessed using the non-parametric statistical test ANOSIM (analysis of 461 
similarities). 462 
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Legends 601 
Fig. 1. Ecological β-diversity of the fecal microbiota in the IBS subtypes. Principal coordinates 602 
analysis of weighted (A) and unweighted (B) Unifrac distances based on the medians of OTU 603 
abundances related to five fecal samples per IBS patient (n = 39). The first two coordinates (PC1 604 
and PC2) are displayed with the percentage of variance explained in brackets. 605 
Fig. 2. OTUs distinguishing IBS subtypes determined using the DESeq2 negative binomial 606 
distribution method on the 16S rRNA gene profiling data of five fecal samples per patient. A, Venn 607 
diagrams summarizing the number of OTUs that discriminate IBS subtypes on the basis of 16S 608 
rRNA gene profiling data of a single sample (single profiling data) and five samples (median 609 
profiling data) per patient. C, IBS with constipation (IBS-C); D, IBS with diarrhea (IBS-D); U, 610 
unsubtyped IBS (IBS-U). Overrepresented OTUs are reported with the same letter color indicating 611 
the IBS subtype. B, IBS subtype-discriminating OTUs according to median profiling data and their 612 
correlation with host physiological and clinical parameters. OTUs that also distinguished IBS 613 
subtypes according to the single profiling data analysis are reported in bold. The heatmap on the left 614 
represents the mean normalized relative abundances of the reported OTUs. The taxonomic lineage 615 
of each taxon is shown; p, phylum; c, class; o, order; f, family; g, genus; s, species. Positive fold 616 
changes (shown on a red background) designate OTU overrepresentation in the IBS subtype 617 
indicated in the column to the left of the Normalized Base Mean; negative fold changes (shown on a 618 
green background) designate the OTU overrepresentation in the IBS subtype indicated in the 619 
column to the right of the Normalized Base Mean. The heatmap in the right panel represents the R-620 
value of Spearman’s correlation between the OTU and host parameters. Asterisks indicate the 621 
Kendall rank correlation: *, P<0.05; **, P<0.01; ***, P<0.001. Black margins around boxes 622 
indicate that the correlations remained significant (according to Kendall’s p value) when determined 623 
using individual sample data. 624 
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Fig. 3. Short-chain fatty acids (SCFAs) in fecal samples of IBS patients. A, Medians of SCFA 625 
concentrations in five fecal samples (wet weight) per IBS patient (n=37; IBS-D, n=11; IBS-C, 626 
n=12; IBS-U, n=11; IBS-M, n=3) and in healthy controls (n=25; data from (Gargari et al., 2016)). 627 
Significance was determined using the Mann-Whitney test; *, P<0.05; **, P<0.01. B, Principal 628 
component analysis (PCA) biplot of SCFAs (represented by arrows) and IBS patients. The first two 629 
coordinates (PC1 and PC2) are displayed with the percentage of variance explained in brackets. 630 
Fig. 4. Correlations among short-chain fatty acids (SCFAs), physiological data and clinical 631 
parameters. The analysis was performed using median data. The heatmap represents the R-value of 632 
Spearman’s correlation. Asterisks indicate the Kendall rank correlation: *, P<0.05; **, P<0.01; ***, 633 
P<0.001. Black margins around boxes indicate that the correlations remained significant (according 634 
to Kendall’s p value) when determined using individual sample data. 635 
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OTU IBS-U IBS-C log2 Fold Change padj Tanonomy
OTU2423305 -2.62 1.1E-02 p_Actinobacteria;c_Coriobacteriia;o_Coriobacteriales;f_Coriobacteriaceae;g_;s_ * ***
ncur_OTU43120 1.90 2.0E-02 p_Actinobacteria;c_Actinobacteria;o_Actinomycetales;f_Actinomycetaceae;g_Actinomyces;s_
OTU4336943 -3.02 1.5E-03 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_;s_
OTU552988 -2.62 6.0E-04 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * * * ** * * *
OTU537219 -2.30 9.4E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_
OTU700540 -2.20 1.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * *
OTU815179 -2.11 1.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * ** ** ** * ** * ** *** **
nr_OTU249 -1.74 1.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * ** *
OTU310178 -3.72 6.9E-07 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ *** * * ** * *** * ** ***
OTU345944 -2.22 4.3E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ *
OTU410242 -1.86 3.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ *
OTU555547 -1.64 1.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ * ** ** ** *** *** *
OTU192240 -2.13 1.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_;s_ * * * *
OTU548021 -2.69 1.5E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ * *
OTU436032 -2.00 1.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia;s_ **
OTU349257 -2.30 1.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Lachnospira;s_
OTU369827 -3.99 2.6E-07 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ * * *** ** *
OTU342947 -2.13 2.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ ** *
OTU564320 -1.99 2.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ * * * ** * *
OTU369602 -4.38 2.6E-07 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ * * *
OTU197943 -2.65 1.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ *
OTU441934 2.49 2.5E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_
OTU174516 2.00 3.3E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_Clostridium;s_
OTU196332 1.60 2.7E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia;s_ * * *
OTU369763 1.99 3.3E-02 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Coprobacillus;s_ * * *
OTU1820513 -2.08 2.7E-02 p_Proteobacteria;c_Betaproteobacteria;o_Burkholderiales;f_Alcaligenaceae;g_Sutterella;s_
OTU IBS-U IBS-D log2 Fold Change padj Tanonomy
OTU530653 -3.00 4.4E-04 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella;s_copri **
OTU107044 -2.05 2.0E-02 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae
OTU4035247 -1.90 4.5E-02 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_;s_
OTU185961 -3.22 8.1E-05 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_
OTU192226 -2.10 2.0E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_[Ruminococcus];s_ * *
OTU341777 -2.20 2.6E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Oscillospira;s_
OTU524884 -3.41 8.7E-04 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_[Eubacterium];s_biforme ** * **
nr_OTU436 -2.13 8.1E-03 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_[Eubacterium];s_biforme * * * ***
OTU197105 -1.87 3.2E-02 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_[Eubacterium];s_biforme * * * **
OTU191421 2.09 4.5E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ *** * * ** *** ** *
OTU360890 2.32 3.0E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ ** * * * ** *
OTU583974 2.00 5.7E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ * * *
OTU584978 2.44 5.7E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_
OTU183532 2.13 1.5E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ *
OTU287608 2.77 3.9E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_
OTU342427 2.28 1.9E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Veillonella;s_dispar * * *
OTU592616 2.23 2.2E-02 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_;s_ *
OTU233953 2.03 1.9E-02 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Coprobacillus;s_ * * *
OTU1820513 -2.37 8.1E-03 p_Proteobacteria;c_Betaproteobacteria;o_Burkholderiales;f_Alcaligenaceae;g_Sutterella;s_
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OTU IBS-C IBS-D log2 Fold Change padj Tanonomy
ncur_OTU62157 -1.42 4.5E-02 p_Actinobacteria;c_Coriobacteriia;o_Coriobacteriales;f_Coriobacteriaceae;g_Collinsella;s_aerofaciens * * * *
ncur_OTU47315 1.63 3.3E-02 p_Actinobacteria;c_Actinobacteria * *
nr_OTU225 1.80 2.0E-02 p_Actinobacteria;c_Actinobacteria;o_Bifidobacteriales;f_Bifidobacteriaceae;g_Bifidobacterium;s_adolescentis
ncur_OTU34595 1.83 1.0E-02 p_Actinobacteria;c_Actinobacteria;o_Bifidobacteriales;f_Bifidobacteriaceae;g_Bifidobacterium;s_adolescentis
OTU1105984 -1.74 2.9E-02 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ *
OTU521927 -1.58 4.5E-02 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ *
OTU195508 -2.18 8.4E-03 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_caccae *
OTU577294 -2.02 1.8E-02 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromonadaceae;g_Parabacteroides;s_distasonis
OTU530653 -3.03 6.2E-05 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella;s_copri **
OTU588929 -2.43 2.0E-03 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella;s_copri *
OTU592925 -2.38 2.1E-02 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella;s_copri
OTU583117 1.57 3.2E-02 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ * * * ** *
OTU197517 2.12 6.0E-03 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Barnesiellaceae];g_;s_ *
OTU4336943 2.53 5.8E-03 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_;s_
OTU185961 -2.70 3.5E-04 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_
nr_OTU145 -2.01 2.5E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * * * * *
OTU174516 -1.70 4.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_Clostridium;s_
OTU197760 -1.35 4.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae ** ** ** * **
OTU158264 -1.18 3.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae * * *
OTU591671 -1.09 2.2E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae ** * ***
OTU531539 -1.92 2.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ * *
OTU362947 -1.89 1.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_
OTU192226 -2.34 2.1E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_[Ruminococcus];s_ * *
OTU514086 -2.05 1.6E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia *
OTU550013 -1.68 1.2E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia;s_ *
OTU189899 -2.29 1.2E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_
OTU194933 -1.52 1.5E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ *** *** **
OTU701221 -1.52 4.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_
ncur_OTU46079 -1.34 3.3E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ ** *** *** *** ***
OTU366794 -1.33 1.7E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ ** ** *
OTU194875 -1.22 2.3E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ ** ** *
OTU196787 -1.11 4.5E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ ** *** **
OTU194672 -1.45 4.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Faecalibacterium;s_prausnitzii ** *
OTU197499 -1.37 9.9E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Faecalibacterium;s_prausnitzii *** * *** *
OTU189210 -1.21 3.8E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Faecalibacterium;s_prausnitzii *** *** **
OTU366068 -1.19 3.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Faecalibacterium;s_prausnitzii ** * *** **
OTU183048 -1.12 4.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Faecalibacterium;s_prausnitzii ** *** **
OTU304211 -1.65 2.8E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ * * * ***
nr_OTU343 -1.91 2.2E-02 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_[Eubacterium];s_biforme * * * ***
nr_OTU436 -1.76 1.3E-02 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_[Eubacterium];s_biforme * * * ***
OTU197105 -1.71 2.1E-02 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_[Eubacterium];s_biforme * * * ***
OTU369763 -2.10 8.3E-03 p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Coprobacillus;s_ * * *
ncur_OTU48808 1.59 9.1E-03 p_Firmicutes;c_Clostridia;o_Clostridiales * * *
OTU353784 1.61 4.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales * ** ** ** *
OTU178511 1.58 2.0E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * ** * * * *
nr_OTU440 1.83 4.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ ** * * **
OTU368025 1.98 6.0E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ *** * * ** *** * *
nr_OTU249 1.98 7.4E-04 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * ** *
OTU1110312 2.05 6.0E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * *
OTU368412 2.14 6.0E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * *
OTU644244 2.65 6.0E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * * * ** ** *
OTU815179 2.77 2.9E-05 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * ** ** ** * ** * ** *** **
OTU191421 3.18 4.4E-05 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ *** * * ** *** ** *
OTU552988 3.23 1.0E-06 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ * * * ** * * *
OTU360890 3.78 1.9E-06 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ ** * * * ** *
OTU555547 1.88 9.0E-04 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ * ** ** ** *** *** *
OTU289454 1.98 1.5E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ ** * * * *** * *** *** *
OTU345944 2.16 2.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ *
OTU310178 4.67 2.3E-11 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_;s_ *** * * ** * *** * ** ***
OTU166896 1.41 4.0E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_;s_ *
OTU192240 1.58 4.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_;s_ * * * *
OTU181466 1.66 2.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_;s_ * * * ** **
nr_OTU26 1.56 4.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ ** * ** * *
OTU548021 2.67 4.0E-04 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ * *
OTU554176 1.31 3.3E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Anaerostipes;s_ * * * ** ** *
nr_OTU148 1.73 6.0E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia;s_ **
OTU436032 2.31 6.3E-04 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia;s_ **
OTU196791 1.97 9.1E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Dorea;s_ ** ** * **
nr_OTU434 1.88 1.3E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae
OTU182044 1.71 2.8E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ * ** * *
OTU584978 1.89 2.1E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_
OTU342947 1.92 2.0E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ ** *
OTU369827 4.67 2.6E-11 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_;s_ * * *** ** *
nr_OTU45 1.70 2.0E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Oscillospira;s_ ** * ** ** * * * ***
OTU364341 1.79 2.0E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Oscillospira;s_ ** * *
OTU582652 1.33 2.8E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ *** *** * **
OTU356011 1.77 3.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_
ncur_OTU21274 1.85 5.0E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ * ** * * * *
OTU183532 2.05 6.4E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ *
ncur_OTU51465 2.12 1.6E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ ** * *
OTU287608 2.58 2.3E-03 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_
OTU369602 3.54 4.5E-05 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus;s_ * * *
OTU342427 1.78 4.4E-02 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Veillonella;s_dispar * * *
OTU1107784 -1.34 4.7E-02 p_Proteobacteria;c_Epsilonproteobacteria;o_Campylobacterales;f_Helicobacteraceae *
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